Halozyme Therapeutics, Inc. (HALO)
Healthcare • Biotechnology
StockNasdaqGSUnited StatesUS40637H1095
Kyvero is an independent information site. It is not affiliated with, endorsed by or sponsored by Halozyme Therapeutics, Inc., and has no access to any account you may have with it. The name and the logo belong to their owners.
Price history
Daily prices in USD. Dividends, results and news are marked on the day they happened; click a day to see them.
Updated 13 Nov 2026 14:12. Information, not advice. Showing the last 12 months. Create a free account to see the whole history
Results
Earnings per share: estimate and reported
Estimate Reported: beat Reported: miss In line
Quarterly results
| Date | EPS estimate | EPS reported | Surprise | Result |
|---|---|---|---|---|
| 16 Feb 2027 16:00 | 2.63 | — | — | Upcoming |
| 05 Nov 2026 16:00 | 2.36 | 2.39 | +1.5% | Beat |
| 06 Aug 2026 16:00 | 1.82 | 2.28 | +25.5% | Beat |
| 11 May 2026 16:00 | 1.52 | 1.60 | +5.3% | Beat |
| 17 Feb 2026 16:00 | 2.20 | -0.24 | -110.9% | Miss |
| 03 Nov 2025 16:00 | 1.63 | 1.72 | +5.5% | Beat |
| 05 Aug 2025 16:00 | 1.27 | 1.54 | +21.5% | Beat |
| 06 May 2025 16:00 | 0.95 | 1.11 | +17.1% | Beat |
| 18 Feb 2025 16:00 | 1.16 | 1.26 | +8.7% | Beat |
| 31 Oct 2024 16:00 | 1.00 | 1.27 | +27.1% | Beat |
| 06 Aug 2024 16:00 | 0.76 | 0.91 | +20.1% | Beat |
| 07 May 2024 16:00 | 0.70 | 0.79 | +13.6% | Beat |
| 20 Feb 2024 16:00 | 0.83 | 0.82 | -1.4% | Miss |
| 06 Nov 2023 16:00 | 0.71 | 0.75 | +6.1% | Beat |
| 08 Aug 2023 16:00 | 0.64 | 0.74 | +15.3% | Beat |
| 09 May 2023 16:00 | 0.48 | 0.47 | -3.0% | Miss |
| 21 Feb 2023 16:00 | 0.47 | 0.48 | +3.0% | Beat |
| 08 Nov 2022 16:00 | 0.51 | 0.74 | +44.0% | Beat |
| 09 Aug 2022 16:00 | 0.50 | 0.53 | +5.0% | Beat |
| 10 May 2022 16:00 | 0.49 | 0.47 | -5.0% | Miss |
| 22 Feb 2022 16:00 | 0.41 | 0.42 | +3.3% | Beat |
| 02 Nov 2021 16:00 | 0.48 | 0.55 | +15.7% | Beat |
| 09 Aug 2021 16:00 | 0.44 | 0.66 | +51.5% | Beat |
| 10 May 2021 16:00 | 0.31 | 0.37 | +18.6% | Beat |
| 23 Feb 2021 16:00 | 0.54 | 0.50 | -7.4% | Miss |
| 02 Nov 2020 16:00 | 0.21 | 0.25 | +21.9% | Beat |
| 10 Aug 2020 16:00 | 0.25 | 0.19 | -22.8% | Miss |
| 11 May 2020 16:00 | -0.04 | -0.04 | -3.5% | Miss |
| 24 Feb 2020 16:00 | -0.14 | -0.24 | -67.6% | Miss |
| 12 Nov 2019 16:00 | -0.13 | -0.17 | -33.1% | Miss |
| 06 Aug 2019 16:00 | -0.15 | -0.10 | +33.7% | Beat |
| 07 May 2019 16:00 | 0.05 | 0.01 | -78.3% | Miss |
| 21 Feb 2019 16:00 | -0.03 | -0.01 | +60.1% | Beat |
| 06 Nov 2018 16:00 | -0.23 | -0.19 | +15.7% | Beat |
| 07 Aug 2018 16:00 | -0.22 | -0.16 | +25.7% | Beat |
| 10 May 2018 16:00 | -0.22 | -0.19 | +14.3% | Beat |
| 20 Feb 2018 16:00 | 0.77 | 0.85 | +11.1% | Beat |
| 07 Nov 2017 16:00 | -0.11 | 0.02 | +118.2% | Beat |
| 08 Aug 2017 16:00 | -0.24 | -0.23 | +5.5% | Beat |
| 09 May 2017 16:00 | -0.24 | -0.26 | -6.3% | Miss |
| 28 Feb 2017 16:00 | -0.30 | -0.21 | +29.5% | Beat |
| 07 Nov 2016 16:00 | -0.26 | -0.23 | +13.1% | Beat |
| 09 Aug 2016 16:00 | -0.28 | -0.21 | +26.1% | Beat |
| 09 May 2016 16:00 | -0.22 | -0.16 | +26.8% | Beat |
| 29 Feb 2016 16:00 | -0.03 | 0.03 | +198.9% | Beat |
| 09 Nov 2015 16:00 | -0.16 | -0.19 | -16.7% | Miss |
| 10 Aug 2015 16:00 | -0.09 | 0.02 | +122.3% | Beat |
| 11 May 2015 16:00 | -0.13 | -0.12 | +9.7% | Beat |
| 02 Mar 2015 16:00 | -0.07 | -0.04 | +41.9% | Beat |
| 10 Nov 2014 16:00 | -0.14 | -0.16 | -16.9% | Miss |
Annual results · USD
| Year | Revenue | Change | Net income | Net margin | EPS | EPS change | Free cash flow |
|---|---|---|---|---|---|---|---|
| 2025 | 1.4B | +37.6% | 316.9M | 22.7% | 2.56 | -25.4% | 356.8M |
| 2024 | 1B | +22.4% | 444.1M | 43.7% | 3.43 | +63.3% | 468.4M |
| 2023 | 829.3M | +25.6% | 281.6M | 34.0% | 2.10 | +45.8% | 373.3M |
| 2022 | 660.1M | — | 202.1M | 30.6% | 1.44 | — | 235.3M |
| 2021 | — | — | — | — | — | — | — |
Dates and earnings per share from the company reports as collected by the data provider; the estimate is the analysts' average before the report. Information, not advice.
Prices by day, week and month
| Period | Opening price | High | Low | Closing price | Change | Volume | Dividend |
|---|---|---|---|---|---|---|---|
| 12 Nov 2026 | 101.58 | 102.14 | 100.27 | 100.67 | -0.99% | 1,430,800 | |
| 11 Nov 2026 | 101.26 | 102.62 | 99.27 | 101.68 | -1.26% | 2,505,000 | |
| 10 Nov 2026 | 101.92 | 105.45 | 101.38 | 102.98 | +0.06% | 2,246,900 | |
| 09 Nov 2026 | 103.98 | 105.64 | 101.04 | 102.92 | -0.69% | 2,926,700 | |
| 06 Nov 2026 | 117.03 | 118.26 | 102.52 | 103.63 | -15.72% | 6,162,600 | |
| 05 Nov 2026 | 130.64 | 131.44 | 122.77 | 122.96 | -5.66% | 2,888,900 | |
| 04 Nov 2026 | 130.81 | 130.98 | 126.86 | 130.34 | +1.34% | 1,612,900 | |
| 03 Nov 2026 | 128.29 | 131.36 | 128.26 | 128.62 | -0.26% | 1,494,900 | |
| 02 Nov 2026 | 130.50 | 131.89 | 127.52 | 128.95 | -1.50% | 3,364,100 | |
| 30 Oct 2026 | 132.66 | 134.00 | 130.31 | 130.91 | -0.21% | 1,402,200 | |
| 1,249 older periods: create a free account to see the whole history | |||||||
Prices in USD, adjusted for splits but not for dividends. Weeks run Monday to Friday and months follow the calendar; the change compares each close with the previous period's. Dividends are those whose ex-dividend date falls in the period, per share. Information, not advice.
News
- Halozyme Therapeutics (HALO) Stock Gets Fair Value Boost After Q3 Analyst Revisions (opens in a new tab) Simply Wall St. · 12 Nov 2026 12:13
- Halozyme Therapeutics (HALO) Stock Looks In Line As ENHANZE Approval Lands (opens in a new tab) Simply Wall St. · 12 Nov 2026 11:12
- Can You Make Money Off Halozyme Stock Now? (opens in a new tab) Trefis · 11 Nov 2026 20:55
- Halozyme Therapeutics' Current Royalty Portfolio Expected to Peak in 2029, Morgan Stanley Says (opens in a new tab) MT Newswires · 11 Nov 2026 16:11
- Will HALO's Partner Royalties Drive Growth for the Rest of 2026? (opens in a new tab) Zacks · 11 Nov 2026 16:11
- Morgan Stanley Downgrades Halozyme Therapeutics to Equal-Weight, Raises Price Target to $109 (opens in a new tab) Benzinga · 11 Nov 2026 13:48
- Halozyme Therapeutics (HALO) is an Incredible Growth Stock: 3 Reasons Why (opens in a new tab) Zacks · 10 Nov 2026 19:42
- Halozyme Therapeutics, Inc. 2026 Q3 - Results - Earnings Call Presentation (opens in a new tab) SeekingAlpha · 10 Nov 2026 18:34
- Are Medical Stocks Lagging Halozyme Therapeutics (HALO) This Year? (opens in a new tab) Zacks · 10 Nov 2026 13:40
- HALO Q3 2026 deep dive: royalty expansion and next-gen platform investments drive outlook update (opens in a new tab) StockStory · 10 Nov 2026 11:49
- Leerink Partners Downgrades Halozyme Therapeutics to Market Perform, Raises Price Target to $117 (opens in a new tab) Benzinga · 06 Nov 2026 20:51
- Halozyme Therapeutics (HALO) Following Record Results And Higher Guidance Is The Stock Still Undervalued (opens in a new tab) Simply Wall St. · 06 Nov 2026 17:15
- Halozyme Stocks Slip 4.28% Despite 39% Revenue Growth and Modestly Higher Guidance (opens in a new tab) GuruFocus.com · 06 Nov 2026 16:58
- Halozyme Stock Down Despite Q3 Earnings and Revenue Beat (opens in a new tab) Zacks · 06 Nov 2026 15:58
- Halozyme Reaffirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Medicare Drug Price Negotiation Program Final Rule for IPAY 2029 (opens in a new tab) 06 Nov 2026 15:04
Headlines link to the original articles of the publishers shown; Kyvero does not write, check or endorse them. Only the most relevant news about each company is kept. Information, not advice.
Key data
- Previous close
- 101.68 USD
- Market cap
- 11.5B
- Exchange
- NasdaqGS
- Country
- United States
- Sector
- Healthcare
- Industry
- Biotechnology
- Currency
- USD
Dividends
No dividends on record.
Why this score
| Part of the score | Points | Why |
|---|---|---|
| Business growth Yearly growth of revenue and of earnings per share. | 25.0 / 25 |
|
| Quality Return on equity, net margin and how stable the margins are. | 16.7 / 25 |
|
| Financial strength Net debt against operating earnings, interest cover and free cash flow. | 19.2 / 20 |
|
| Valuation Free cash flow yield and the P/E against its sector. | 11.0 / 15 |
|
| Analysts How far the analysts' average target is from today's price. | 9.7 / 10 |
|
Growth profile: it pays no dividend, so it is scored on business growth, quality and financial strength. Based on 95% of the figures (grade A).
Warnings take points off and some cap the score. In your account the score also considers how the share fits your portfolio. How the score works
Figures
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| P/E (trailing) | 25.42× | Weak | 30.56× |
| P/E (forward) | 9.6× | Good | 14.16× |
| Price / book | -209.65× | Weak | 3.5× |
| Price / sales | 6.43× | Weak | 3.33× |
| EV / EBITDA | 12.1× | Fair | 11.19× |
| Free cash flow yield | 3.7% | Fair | 2.1% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Gross margin | 76% | Good | 54.9% |
| Operating margin | 56.7% | Good | 5.8% |
| Net margin | 26.9% | Good | 1.2% |
| Return on equity | 216.4% | Good | 4.4% |
| Return on assets | 22.4% | Good | 2.7% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Revenue growth / year | 28.4% | Good | 10.1% |
| EPS growth / year | 21.1% | Good | 10.2% |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Debt / equity | 43.89× | Weak | 0.4× |
| Net debt / EBITDA | 1.93× | Fair | 1.46× |
| Interest cover | 44.28× | Good | 2.17× |
| Current ratio | 3.88× | Good | 2.64× |
| Figure | Value | Reading | Sector median |
|---|---|---|---|
| Payout of earnings | 0% | Weak | 0% |
The reading follows general rules of thumb and each sector has its own norms: compare with the sector median when it is shown. Information, not advice.
Similar shares
Follow HALO and get alerts
Create a free account to add it to your watchlist, set a price alert, see how it fits your portfolio and track your dividends.